ScripAfter a year littered with clinical failures for its cancer vaccine UV1, Ultimovacs has managed to secure survival by combining with fellow Norwegian biotech Zelluna Immunotherapy. The deal is structu
In VivoEstablished only last year and incorporated in France and Spain with an initial seed from Paris-based VC firm AdBio Partners, Kiji Therapeutics is grounded in science from the Spanish public research